Navigation Links
BSP's New Line of HyperQ Products: Bedside Ischemia Monitoring Systems Announces Successful Results of First Feasibility Study

BSP's HyperQ(TM) Monitoring System will Allow Bedside Detection of Ischemic

Events and Myocardial Infarction (Heart Attack)

TEL AVIV, Israel, February 26 /PRNewswire/ -- BSP (Biological Signal Processing Ltd.) an Israeli company which develops and markets systems for non-invasive diagnosis and monitoring of ischemic heart disease, announces successful results in detecting ischemic events using its proprietary HyperQ technology in resting conditions.

The successful results of the study indicate that the HyperQ(TM) technology, based on sophisticated analysis of high-frequency ECG components, can be implemented in two products: (i) bedside monitoring system for early detection of transient ischemic episodes and (ii) a resting ECG system for sensitive diagnosis of acute coronary syndrome, including myocardial infarction. A highly important clinical application of these two devices is the identification of heart attacks that are not accompanied by changes in standard ECG.

The results of the study showed that both HyperQ(TM) indices detected ischemia more accurately than ST analysis. Overall accuracy of HyperQ-based analysis was found to be 96% for the intensity-based index and 82% for the morphology-based index, both significantly higher than the accuracy of the conventional ST segment analysis at 75%.

"We are proud to present the first results that indicate clearly the HyperQ's strength in ischemia monitoring in a resting condition," said Dr. Amir Beker, Founder & CEO of BSP. "This carries an immense clinical value to cardiac patients, and marks the feasibility of BSP's next product line - the monitoring and resting HyperQ systems, which are planned to be offered to the market by early 2009. BSP will launch the commercial introduction of the HyperQ(TM) Stress System in the US at the 57th ACC Meeting this March." added Dr. Beker.

About BSP

BSP is dedicated to providing novel, risk free and highly reliable solutions for the diagnosis and monitoring of Ischemic Heart Disease. BSP's HyperQ technology is implemented in cardiac systems that offer highly reliable, low-cost and risk free cardiac monitoring and allows, for the first time, an effective diagnosis of Ischemic Heart Diseases in broad populations. BSP's HyperQ(TM) System for Stress Tests has received FDA clearance and obtained CE marking.

BSP was founded in 2000 by Dr. Amir Beker, and Ariel Landau, had completed a successful IPO in mid-2006 and is traded on the Tel Aviv Stock Exchange.


Dr. Amir Beker,


SOURCE BSP - Biological Signal Processing Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Microtest Offers Free White Paper: Virus Testing for Biological Products: Partnering With a Contract Lab
2. CleveMed Receives $1.5 Million in NIH Funding to Further Develop a Portable System for Monitoring Parkinsons Disease Motor Symptoms
3. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
4. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R)
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety
9. Masimo Launches Patient SafetyNet and Showcases the Rainbow SET Upgradable Noninvasive Monitoring Platform at 2007 ASA Annual Meeting
10. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
11. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
Post Your Comments:
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
(Date:11/25/2015)... 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... a fireside chat discussion at the Piper Jaffray 27th ... . The discussion is scheduled for Wednesday, December 2, ... .  A replay will be available for 14 days ... , Julie NormartVP, Corporate Communications and Business Development , ...
(Date:11/24/2015)... 2015 Cepheid (NASDAQ: CPHD ) today ... following conference, and invited investors to participate via webcast. ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ... New York, NY      Tuesday, December 1, 2015 ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
Breaking Biology Technology:
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
Breaking Biology News(10 mins):